Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a ...

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License ...

The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...

The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...

French drug major Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the U.S. Food and Drug Administration ...

This observation led Swedish investigators to propose, in 1948, that there are two types of receptors sensitive to histamine, and close to two decades later British researchers gave the name H1 to ...

In the following section, the various methods used to evaluate antihistamines illustrate the developmental process for evaluating the efficacy of the H 1-receptor antagonist desloratadine.

In vitro tests have demonstrated that second-generation antihistamines have improved H 1-receptor specificity and a slower dissociation rate compared with first-generation antihistamines ...

For mild hives, your doctor may recommend an over-the-counter, second-generation H1 antihistamine such as fexofenadine (Allegra), loratadine (Claritin), cetirizine (Zyrtec), or desloratadine ...